MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1

Cellular Physiology and Biochemistry

Volumn 33, Issue 5, 2014, Pages 1329-1339

  Xu, Guoxing ^a   Wang, Jin ^a   Jia, Yixin ^a   Shen, Feng ^a   Han, Wensheng ^b   Kang, Yifan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Ultrasound   (China)

Author keywords

HMGA1; miR 142 3p; Osteosarcoma; Tumor suppressor

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; MICRORNA; MIR 142 3P; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; HIGH MOBILITY GROUP A1A PROTEIN; MIRN142 MICRORNA, HUMAN; MICRORNA 142 3P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL MOTION; DOSE RESPONSE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE; COLONY FORMATION; IN VITRO STUDY; OSTEOSARCOMA CELL; PROTEIN RNA BINDING; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS MUSCULUS;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HMGA1A PROTEIN; HUMANS; MICE; MICE, NUDE; MICRORNAS; OSTEOSARCOMA; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899606753     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358700     Document Type: Article

References (30)

1. Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13.
2. Kansara M, Thomas DM: Molecular Pathogenesis of Osteosarcoma. DNA Cell Biol 2007;26:1-18. (Pubitemid 46219587)
3. Gorlick R: Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009;152:467-478.
4. Osaki M, Takeshita F, Sugim oto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M, Ochiya T: MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expres sion. Mol Ther 2011;19:1123-1130.
5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
6. Calin GA, Croce CM: MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006;25:6202-6210. (Pubitemid 44527851)
7. Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
8. Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 2003;113:673-676. (Pubitemid 36724931)
9. Lu J Getz G Miska EA Alvarez-Saavedra E Lamb J Peck D Sweet-Cordero A Ebert BL Mak RH Ferrando AA Downing JR Jacks T Horvitz HR Golub TR.MicroRNA expression profiles classify human cancers, Nature2005; 435; 834-838. (Pubitemid 40839735)
10. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodsta O, Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-4074
11. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI: MiRNA signatures associate with pathogene sis and progression of osteosarcoma. Cancer Res 2012;72:1865-1877.
12. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 2010;129:680-690.
13. Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, Hornicek F: MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 2011;10:1337-1345
14. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt p athway in human osteosarcoma. PLoS One 2013;8:e53906.
15. Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM, Cai XH: MiR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ER K1/2 pathway in osteosarcoma. FEBS Lett 2013;587:1366-1372.
16. Van Der Deen M, Taipaleenmaki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, Shogren K, Maran A, Yaszemsk MJ, Ling L, Cool SM, Leong DT, Dierkes C, Zustin J, Salto-Tellez M, Ito Y, Bae SC, Zielenska M, Squire JA, Lian JB, Stein JL, Zambetti GP, Jones SN, Galindo M, Hesse E, Stein GS, Van Wijnen AJ: MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem 2013;288:21307-21319.
17. Wu L, Cai C, Wang X, Liu M, Li X, Tang H: MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett 2011;585:1322-1330.
18. Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, Liu N, Yu Y, Gao D, Huang BT, Wang J, Zhou DB, Gong JN, Zhao HL, Bi XH, Yu J, Zhang JW: MiR-29a and miR-142-3p downregulation and diagno stic implication in human acute myeloid leukemia. Mol Biol Rep 2012;39:2713-2722.
19. Shen WW, Zeng Z, Zhu WX, Fu GH: MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl) 2013;91:989-1000.
20. MacKenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S, Saluja AK: Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 2013;12:1266-1275.
21. Naml0s HM, Meza-Zepeda LA, Bar0y T, 0stensen IH, Kresse SH, Kuijjer ML, Serra M, Burg er H, Cleton-Jansen AM, Myklebost O: Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 2012;7:e48086.
22. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, L iu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 2012;84:320-330.
23. Fedele M, Fusco A: HMGA and cancer. Biochim Biophys Acta 2010;1799:48-54.
24. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, Resar LM: HMG-I/Y: A new c-Myc target gene and potential human oncogene. M ol Cell Biol 2000;20:5490-5502. (Pubitemid 30482886)
25. Reeves R, Edberg DD, Li Y: Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001; 21:575-594. (Pubitemid 32037376)
26. Xu Y, Sumter TF, Bhattacharya R, Tesfaye A, Fuchs EJ, Wood LJ, Huso DL, Resar LM: The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64:3371-3375. (Pubitemid 38657906)
27. Wood LJ, Maher JF, Bunton TE, Resar LM: The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-4261. (Pubitemid 30636614)
28. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C, Viglietto G, Croce CM, Fusco A: Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymph omas. Oncogene 2005;24:3427-3435. (Pubitemid 40756244)
29. Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC Jr, Sukumar S, Huso DL, Resar LM: HMGA1: A Master Regulator of Tumor Progression in Triple-Negativ e Breast Cancer Cells. PLoS One 2013;8:e63419.
30. Yuan S, Pan Q, Fu C, Bi Z: Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma. Mol Cell Biochem 2011;355:281-287.